Secondary central nervous system lymphoma (SCNSL) occurred in about 5% of patients with
diffuse large B-cell lymphoma (DLBCL). The prognosis of SCNSL is very poor. A number of
retrospective studies have shown that the median overall survival (mOS) since the diagnosis
of CNSL is only 2.5-3.5 months, and the 2-year OS rate is only 20%. At present, there is no
consensus on the treatment of SCNSL, and new therapeutic strategies are urgently needed.
Zanubrutinib is a new second-generation BTK inhibitor, which has showed good efficacy and
safety in a variety of B-NHL. Zanubrutinib has showed good blood-brain barrier permeability
in preclinical studies. This study attempts to evaluate the efficacy and safety of
zanubrutinib combined with rituximab and high-dose methotrexate in the treatment of SCNSL in
patients with DLBCL.